NCT01146067

Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions

Bioequivalence Study of Rivastigmine 1.5 mg Capsules (Test)of Dr.Reddy's Laboratories Limited Versus Exelon (Reference),Administered as 1 x 1.5 mg Capsule Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Dr. Reddy's Laboratories Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a bioequivalence study of Rivastigmine 1.5 mg capsules and Exelon Administered as 1.5 mg capsule in Healthy subjects under fasting conditions.

Detailed description

Single center, bioequivalence, open-label, randomized, 2-way crossover study administered as 1 x 1.5 mg capsule in healthy subjects under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Rivastigmine	Rivastigmine capsules 1.5 mg

Timeline

• Start date: 2004-01-01
• Primary completion: 2004-02-01
• Completion: 2004-02-01
• First posted: 2010-06-17
• Last updated: 2012-01-13